< Back to latest news & events

News

G3/19: A further Referral to the Enlarged Board of Appeal on Plants Produced by Essentially Biological Processes

June 2019

In decision T1063/18, a EPO Technical Board of Appeal created controversy in ruling that the jurisprudence of the Enlarged Board of Appeal took precedence over Rule 28(2) of the EPC. The Board held that decisions G2/12 and G2/13 should be followed in preference to the rule, thus allowing claims to plants produced by essentially biological processes.

T1063/18 created uncertainty as to how the EPO would deal with this conflict; were examiners to follow the rules or the Board’s precedent? Many expected that the EPO would have to take action to clarify the legal situation, and many hoped that there would be a referral to the Enlarged Board of Appeal. This has now happened.

To give a little more background, we first reported back in December 2018 on T1063/18 that the Board considered that controversial R.28(2) EPC is in conflict with A.53(b) EPC, as interpreted in both the Enlarged Board decisions G2/12 and G2/13 (“broccoli II” and “tomatoes II”), and was therefore improper. As a result of this, the Board held that R.28(2) EPC should be ignored, and that plants produced by essentially biological processes are indeed patentable.

In the EPO Official Journal for May 20191, it was announced that the President of the EPO has now referred questions regarding this point of law to the Enlarged Board under case number G3/19. The questions referred by the President are as follows:

  1. Having regard to Article 164(2) EPC, can the meaning and scope of Article 53 EPC be clarified in the Implementing Regulations to the EPC without this clarification being a priori limited by the interpretation of said article given in an earlier decision of the boards of appeal or the Enlarged Board of Appeal?
  2. If the answer to question 1 is yes, is the exclusion from patentability of plants and animals exclusively obtained by means of an essentially biological process pursuant to Rule 28(2) EPC in conformity with Article 53(b) EPC which neither explicitly excludes nor explicitly allows said subject-matter?

There is some disagreement as to whether the referral is admissible, given that two Enlarged Board of Appeal decisions have already dealt with the patentability of plants and animals exclusively obtained by means of an essentially biological process; G2/12 and G2/13. Furthermore, there do not appear to be conflicting T decisions on this matter. However, in the grounds for referral2, the President argues that there is different case law on the way the existence of a conflict between Article 53 EPC and a Rule which clarifies its meaning and scope is examined under Article 164(2) EPC. Thus, the questions are admissible. The President further argues that the purpose of the President’s right of referral under Article 112(1)(b) EPC is to establish uniformity of law and legal certainty within the European patent system, and that the point of law raised in T1063/18 is of fundamental importance.  We concur that clarity on this area is certainly needed.

It is not yet known whether the Enlarged Board of Appeal will decide on this referral or whether they will deem it inadmissible. However, the EPO has announced3 that any cases whose outcome depends entirely on the Enlarged Board decision will be stayed pending the outcome.

The deadline for filing third party statements is 1st October 2019. We will provide further updates as and when they are announced.

[1] – https://epo.org/law-practice/legal-texts/official-journal/2019/05/a52.html

[2] – https://documents.epo.org/projects/babylon/eponet.nsf/0/4F62ECCAF1B2F2F5C12584020026796E/$File/Referral%20under%20Art.%20112(1)(b)%20EPC-%20G%203-19.pdf

[3] – https://www.epo.org/law-practice/legal-texts/official-journal/information-epo/archive/20190410.html

This update was prepared by HGF Senior Patent Attorney Ellie Purnell.  If you would like further advice on this or any other matter, please contact Ellie Purnell. Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

HGF Ranked #1 in the UK for Trade Mark Portfolios in the 2025 Trade Mark Filing Trends Report by Clarivate.

HGF has achieved the #1 ranking for the UK for trade mark portfolios in the newly released 2025 Trade mark Filing Trends report by Clarivate, recognising the firm as a …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Agritech Thymes: Agritech 2030: Forecasting the Technologies Poised to Transform Farming

Whilst yet to recover to the levels of 2011-2021, where capital invested in agritech increased 20-fold, investor funding in agritech is starting to pick up, and 2025 is set to …

Read article

UPC delivers first judgment on Validity and Infringement of a Second Medical Use Claim

Sanofi Biotechnology SAS & Anor v Amgen, Inc., & Ors– Thomas, Thom, Kupecz and Dorland-Galliot – [UPC_CFI_505/2024] The Dusseldorf Local Division (LD) has delivered the UPC’s first Judgment on second …

Read article
Event - 25th June 2025

Webinar: Patent and trademark strategy for start-ups - protecting innovation, building a brand, securing growth

Start-ups thrive on ideas – and on protecting them. However, patents and trademarks are often protected too late or insufficiently. HGF is pleased to invite you to participate in our …

Event details
Event - 26th - 27th June 2025

10th Intellectual Property and Competition Forum in Amsterdam

We are pleased to announce that our partner and patent attorney Bernhard Ganahl will be a panelist at the 10th IP and Competition Forum of OxViews in Amsterdam. At the …

Event details

IP Ingredients: What Will The EU’s Design Reform Package Do For Food & Drink Businesses?

As reported by our colleague Joanne Meredith in her recent post (click here to read), Phase One of the EU’s “Design Reform Package” became effective on 1 May 2025, with …

Read article